PWMG
ADMA icon

Prestige Wealth Management Group’s ADMA Biologics ADMA Stock Holding History

Prestige Wealth Management Group’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$344 Sell
41
-272
-87% -$2.48K ﹤0.01% 1063
2026
Q1 		$2.82K Buy
313
+13
+4% +$205 ﹤0.01% 675
2025
Q4 		$5.47K Hold
300
– – ﹤0.01% 558
2025
Q3 		$4.4K Hold
300
– – ﹤0.01% 595
2025
Q2 		$5.46K Hold
300
– – ﹤0.01% 546
2025
Q1 		$5.95K Hold
300
– – ﹤0.01% 525
2024
Q4 		$5.14K Buy
300
+200
+200% +$3.76K ﹤0.01% 594
2024
Q3 		$2K Buy
+100
New +$1.55K ﹤0.01% 770

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Prestige Wealth Management Group's ADMA Position: Q2 2026 in Review

Prestige Wealth Management Group reduced its ADMA Biologics (ADMA) stake by 87% in Q2 2026, selling an estimated $2.48K and leaving 41 shares worth $344. The position accounts for ﹤0.01% of the portfolio, ranked #1063.

Prestige Wealth Management Group first reported a position in ADMA in Q3 2024 and has held it in 8 quarters since. The position peaked at $5.95K in Q1 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Prestige Wealth Management Group held 41 shares of ADMA Biologics worth $344 as of Q2 2026.
  • Prestige Wealth Management Group sold 272 ADMA Biologics shares in Q2 2026, an estimated $2.48K.
  • ADMA Biologics made up ﹤0.01% of Prestige Wealth Management Group's portfolio in Q2 2026, its #1063 holding.
  • Prestige Wealth Management Group first reported a position in ADMA Biologics in Q3 2024 and has held it in 8 quarters since.
  • Prestige Wealth Management Group's ADMA Biologics position peaked at $5.95K in Q1 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Prestige Wealth Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.